Syllabus Edition

First teaching 2023

First exams 2025

|

Gene Technology in Medicine (CIE A Level Biology)

Revision Note

Test Yourself
Phil

Author

Phil

Expertise

Biology Project Lead

Social & Ethical Considerations

  • The use of gene technology (genetic screening and gene therapy) in medicine is becoming more common
  • Genetic screening in medicine is being used to:
    • Allow people with a family history of a genetic disease to have their DNA analysed to determine if they are at risk
    • Carry out pre-implantation genetic diagnosis (PGD) – embryos that are created outside the body (with the IVF procedure) have their DNA analysed, which allows for embryos that are not carrying a harmful allele that would cause the disease, to be chosen for implantation

  • Gene therapy is being used in medicine for introducing corrected copies of genes into patients with genetic diseases (e.g. cystic fibrosis, haemophilia, severe combined immunodeficiency)

Genetic screening

  • There are many social and ethical considerations for genetic screening, which include:
    • Being able to take preventative measures (e.g. elective mastectomy when BRCA1 and BRCA2 are detected) - giving individuals control to prevent illness
    • Using pre-implantation genetic diagnosis to select embryos that do not carry faulty disease-causing alleles
    • This could lead to the fear of ‘‘designer babies’ being created (this includes creating/choosing embryos with tissue matches to older siblings)
    • A pre-implantation genetic diagnosis can be carried out during in-vitro fertilisation (IVF); cells are extracted from the embryo in an embryo biopsy and genetically screened in order to preselect the embryos without faulty alleles
    • Using genetic counsellors to help people understand their choices and make informed decisions (e.g. financial costs, whether termination of the foetus is appropriate if the quality of life is poor)
    • Risk of miscarriage (which has emotional consequences) due to the procedures used to collect DNA which are not 100% risk-free
      • Amniocentesis – is used to obtain a sample of amniotic fluid using a hypodermic needle at 15 to 16 weeks of pregnancy
      • Chorionic villus sampling – is used to obtain a small sample of the placenta using a needle between 10 and 13 weeks of pregnancy

  • Choosing to terminate a pregnancy (therapeutic abortion) because the embryo has a genetic disorder (eg. Thalassaemia or cystic fibrosis) or even terminating the embryo due to a minor ‘defect’ that could have seen the child lead an almost normal life
  • Being able to make informed reproductive decisions (eg. thalassaemia)
  • Determining whether it is best to know the risk of having a disease, especially when there is no cure (eg. Huntington’s)
  • Deciding at what age screening should begin e.g. whether parents should be able to choose for their children to be screened
  • The possibility of stigmatisation and discrimination
    • The person may feel stigmatised if they have the disease or discriminated against by health insurers or employers
  • Confidentiality of the data collected – who will have the right to view the results obtained

Social and Ethical Considerations of Using Gene Therapy

  • The social and ethical considerations of using gene therapy include:
    • The potential for side effects that could cause death (e.g. the children who were treated for SCID developed leukaemia)
    • Whether germline gene therapy (the alteration of genes in egg and sperm cells which results in the alteration being passed onto future generations) should be allowed – it could be a cure for a disease or it could create long-term side effects
    • The commercial viability for pharmaceutical companies – if it is a rare disease, the relatively small number of patients may not mean that the companies will make a profit (eg. Glybera – gene therapy for lipoprotein lipase deficiency is no longer produced as there were too few patients)
    • The expense of treatments as multiple injections of the genes may be required if the somatic cells are short-lived (e.g. severe combined immunodeficiency)
    • This may make the cost of gene therapy accessible to a limited number of people
    • The possibility that people will become less accepting of disabilities as they become less common
    • Who has the right to determine which genes can be altered and which cannot (e.g. should people be allowed to enhance intelligence or height)
    • Another method of enhancing sporting performances unfairly through gene doping
    • This is where the genes are altered to give an unfair advantage eg. to provide a source of erythropoietin (the hormone that promotes the formation of red blood cells)

You've read 0 of your 0 free revision notes

Get unlimited access

to absolutely everything:

  • Downloadable PDFs
  • Unlimited Revision Notes
  • Topic Questions
  • Past Papers
  • Model Answers
  • Videos (Maths and Science)

Join the 100,000+ Students that ❤️ Save My Exams

the (exam) results speak for themselves:

Did this page help you?

Phil

Author: Phil

Phil has a BSc in Biochemistry from the University of Birmingham, followed by an MBA from Manchester Business School. He has 15 years of teaching and tutoring experience, teaching Biology in schools before becoming director of a growing tuition agency. He has also examined Biology for one of the leading UK exam boards. Phil has a particular passion for empowering students to overcome their fear of numbers in a scientific context.